---
figid: PMC7582904__ijms-21-07295-g002
figtitle: Mechanisms for restoring HLA class I expression
organisms:
- NA
pmcid: PMC7582904
filename: ijms-21-07295-g002.jpg
figlink: pmc/articles/PMC7582904/figure/ijms-21-07295-f002/
number: F2
caption: 'Mechanisms for restoring HLA class I expression. IFN binding to IFNR triggers
  Jak/STAT transduction pathway. STAT1/STAT2/IRF complex translocates to the nucleus
  where it binds to ISRE motifs located in HLA promoter region, inducing HLA gene
  transcription. EGFR and MAPK down-stream pathways suppress HLA class I surface expression.
  EGFR inhibitors, such as nimotuzumab, cetuximab and erlotinib, BRAF inhibitors,
  vemurafenib and dabrafenib, and MEK inhibitor trametinib can increase expression
  of both HLA class I antigens and APM components. DNMT inhibitors (azacytidine and
  guadecitabine) and HDAC inhibitors (vorinostat, belinostat, panobinostat, OKI-179,
  romidepsin and tubastatin A) avoid hypermethylation of HLA promoter region and histones
  hypoacetylation that cause HLA genes silencing. Abbreviations: HLA, human leukocyte
  antigen; IFNs, interferons; IFNR, interferon receptor; IRF, IFN regulatory factor;
  ISRE, IFN-sensitive response element; EGF, epidermal growth factor; EGFR, epidermal
  growth factor receptor; DNMT, DNA methyltransferase; HDAC, histone deacetylase;
  APM, antigen-processing machinery.'
papertitle: Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based
  Immunotherapy in Cancer Patients.
reftext: Francesco Sabbatino, et al. Int J Mol Sci. 2020 Oct;21(19):7295.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9653962
figid_alias: PMC7582904__F2
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC7582904__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7582904__ijms-21-07295-g002.html
  '@type': Dataset
  description: 'Mechanisms for restoring HLA class I expression. IFN binding to IFNR
    triggers Jak/STAT transduction pathway. STAT1/STAT2/IRF complex translocates to
    the nucleus where it binds to ISRE motifs located in HLA promoter region, inducing
    HLA gene transcription. EGFR and MAPK down-stream pathways suppress HLA class
    I surface expression. EGFR inhibitors, such as nimotuzumab, cetuximab and erlotinib,
    BRAF inhibitors, vemurafenib and dabrafenib, and MEK inhibitor trametinib can
    increase expression of both HLA class I antigens and APM components. DNMT inhibitors
    (azacytidine and guadecitabine) and HDAC inhibitors (vorinostat, belinostat, panobinostat,
    OKI-179, romidepsin and tubastatin A) avoid hypermethylation of HLA promoter region
    and histones hypoacetylation that cause HLA genes silencing. Abbreviations: HLA,
    human leukocyte antigen; IFNs, interferons; IFNR, interferon receptor; IRF, IFN
    regulatory factor; ISRE, IFN-sensitive response element; EGF, epidermal growth
    factor; EGFR, epidermal growth factor receptor; DNMT, DNA methyltransferase; HDAC,
    histone deacetylase; APM, antigen-processing machinery.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - IFNR
  - IFNAR2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - KRAS
  - HRAS
  - NRAS
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - TRIM63
  - DNMT1
  - DNMT3A
  - DNMT3B
  - DNMT3L
  - ANPEP
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - NFKB1
  - NFYA
  - NFYB
  - NFYC
  - EGFR
  - Egfr
  - Stat92E
  - ras
  - Ras64B
  - Ras85D
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Irp-1B
  - Irp-1A
  - Mt2
  - Nmt
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Dif
  - dl
  - Rel
  - Rex
  - Me
  - x2
  - x1
  - Erlotinib
  - Vemurafenib
  - Dabrafenib
  - Trametinib
  - Azacytidine
  - Guadecitabine
  - Tubastatin A
  - 'NFY MeMe Me '
---
